Mensch, Alexander; Stock, Stephanie; Stollenwerk, Björn; … - In: PharmacoEconomics 33 (2015) 3, pp. 271-283
Our results showed that the substantially higher medication costs of rivaroxaban were offset by mitigating the shortcomings of warfarin, most notably frequent dose regulation and bleeding risk. Future health economic studies on novel oral anticoagulants should evaluate the cost effectiveness for...